Ephedrine treatment in congenital myasthenic syndrome due to mutations in <i>DOK7</i>

Abstract

This study provides Class IV evidence that ephedrine given at doses between 15 and 90 mg/day improves muscle strength in patients with documented mutations in DOK7.